 Catherine Demers
Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| White Matter | 3 | 2024 | 145 | 1.600 |
Why?
| | Mothers | 2 | 2024 | 754 | 0.610 |
Why?
| | Heart Failure | 6 | 2024 | 2236 | 0.550 |
Why?
| | Amygdala | 3 | 2022 | 191 | 0.510 |
Why?
| | Arachidonic Acids | 1 | 2016 | 62 | 0.480 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 2016 | 68 | 0.480 |
Why?
| | Endocannabinoids | 1 | 2016 | 63 | 0.460 |
Why?
| | Hair | 2 | 2024 | 84 | 0.420 |
Why?
| | Anxiety | 2 | 2024 | 1035 | 0.420 |
Why?
| | Diffusion Tensor Imaging | 2 | 2024 | 79 | 0.390 |
Why?
| | Home Care Services | 1 | 2015 | 257 | 0.370 |
Why?
| | Hydrocortisone | 2 | 2024 | 322 | 0.370 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2016 | 2189 | 0.350 |
Why?
| | Longitudinal Studies | 4 | 2025 | 2844 | 0.310 |
Why?
| | Brain | 5 | 2024 | 2668 | 0.280 |
Why?
| | Magnetic Resonance Imaging | 8 | 2025 | 3566 | 0.280 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2024 | 605 | 0.280 |
Why?
| | Pregnancy | 11 | 2025 | 6763 | 0.260 |
Why?
| | Stroke Volume | 3 | 2024 | 612 | 0.250 |
Why?
| | Anhedonia | 1 | 2025 | 13 | 0.240 |
Why?
| | Corpus Striatum | 2 | 2025 | 167 | 0.240 |
Why?
| | Anisotropy | 1 | 2024 | 79 | 0.220 |
Why?
| | Limbic System | 1 | 2024 | 47 | 0.220 |
Why?
| | Gestational Age | 2 | 2024 | 910 | 0.220 |
Why?
| | Flavins | 1 | 2023 | 3 | 0.220 |
Why?
| | Nucleus Accumbens | 1 | 2025 | 138 | 0.210 |
Why?
| | Luciferases | 1 | 2023 | 150 | 0.210 |
Why?
| | Depression, Postpartum | 1 | 2025 | 132 | 0.200 |
Why?
| | Psychotherapy, Brief | 1 | 2023 | 34 | 0.200 |
Why?
| | Infant | 4 | 2025 | 9465 | 0.200 |
Why?
| | Female | 25 | 2025 | 73304 | 0.190 |
Why?
| | Signal Transduction | 1 | 2016 | 5079 | 0.190 |
Why?
| | Sleep | 2 | 2024 | 755 | 0.180 |
Why?
| | Birth Weight | 1 | 2024 | 516 | 0.180 |
Why?
| | Social Behavior | 2 | 2013 | 287 | 0.170 |
Why?
| | Humans | 28 | 2025 | 137585 | 0.160 |
Why?
| | Child Development | 1 | 2024 | 475 | 0.160 |
Why?
| | Prospective Studies | 5 | 2023 | 7604 | 0.160 |
Why?
| | Emotions | 1 | 2024 | 548 | 0.160 |
Why?
| | Racism | 1 | 2021 | 135 | 0.160 |
Why?
| | Depressive Disorder, Major | 1 | 2023 | 364 | 0.150 |
Why?
| | Infant, Newborn | 8 | 2025 | 6079 | 0.150 |
Why?
| | Psychoses, Substance-Induced | 1 | 2019 | 13 | 0.150 |
Why?
| | Premature Birth | 1 | 2022 | 333 | 0.150 |
Why?
| | Gray Matter | 1 | 2019 | 80 | 0.150 |
Why?
| | Stress, Psychological | 3 | 2017 | 1100 | 0.150 |
Why?
| | Atrial Fibrillation | 1 | 2023 | 388 | 0.150 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2426 | 0.150 |
Why?
| | Sex Characteristics | 2 | 2013 | 762 | 0.140 |
Why?
| | Adult | 14 | 2025 | 37929 | 0.140 |
Why?
| | Male | 19 | 2025 | 67762 | 0.140 |
Why?
| | Frontal Lobe | 1 | 2017 | 149 | 0.130 |
Why?
| | Polyunsaturated Alkamides | 1 | 2016 | 8 | 0.120 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2016 | 29 | 0.120 |
Why?
| | Amidohydrolases | 1 | 2016 | 31 | 0.120 |
Why?
| | Marijuana Abuse | 1 | 2019 | 233 | 0.120 |
Why?
| | Depression | 3 | 2023 | 1397 | 0.120 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 1040 | 0.120 |
Why?
| | Genome-Wide Association Study | 2 | 2019 | 1431 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1477 | 0.110 |
Why?
| | Perception | 1 | 2017 | 359 | 0.110 |
Why?
| | Receptors, AMPA | 1 | 2015 | 141 | 0.110 |
Why?
| | Pregnancy Trimester, Third | 2 | 2024 | 114 | 0.110 |
Why?
| | Hypertension | 1 | 2023 | 1295 | 0.110 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2016 | 547 | 0.100 |
Why?
| | Touch | 1 | 2013 | 36 | 0.100 |
Why?
| | Maternal Behavior | 1 | 2013 | 78 | 0.100 |
Why?
| | Cocaine-Related Disorders | 1 | 2013 | 113 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 591 | 0.100 |
Why?
| | Impulsive Behavior | 1 | 2013 | 150 | 0.090 |
Why?
| | Self Concept | 1 | 2013 | 253 | 0.090 |
Why?
| | Pregnancy Complications | 2 | 2024 | 527 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2016 | 752 | 0.090 |
Why?
| | Cardiac Catheterization | 3 | 2023 | 530 | 0.090 |
Why?
| | Oxygen | 1 | 2016 | 931 | 0.090 |
Why?
| | Genotype | 1 | 2016 | 1916 | 0.080 |
Why?
| | Self Care | 1 | 2013 | 380 | 0.080 |
Why?
| | Ventricular Function, Left | 2 | 2023 | 534 | 0.080 |
Why?
| | Behavior, Animal | 1 | 2013 | 501 | 0.080 |
Why?
| | Chronic Disease | 1 | 2015 | 1793 | 0.080 |
Why?
| | Dalteparin | 1 | 2008 | 10 | 0.080 |
Why?
| | Cognitive Dysfunction | 1 | 2013 | 383 | 0.070 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 515 | 0.070 |
Why?
| | Pregnancy Outcome | 3 | 2024 | 416 | 0.070 |
Why?
| | Siblings | 2 | 2019 | 228 | 0.070 |
Why?
| | Caudate Nucleus | 1 | 2025 | 23 | 0.060 |
Why?
| | Putamen | 1 | 2025 | 23 | 0.060 |
Why?
| | Intention to Treat Analysis | 1 | 2025 | 73 | 0.060 |
Why?
| | Organ Size | 1 | 2025 | 477 | 0.060 |
Why?
| | Cardiologists | 1 | 2024 | 45 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2025 | 119 | 0.050 |
Why?
| | Reward | 1 | 2025 | 244 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2023 | 15657 | 0.050 |
Why?
| | Heart Atria | 1 | 2023 | 137 | 0.050 |
Why?
| | Young Adult | 2 | 2016 | 13209 | 0.050 |
Why?
| | Canada | 1 | 2023 | 418 | 0.050 |
Why?
| | Telomere Shortening | 1 | 2022 | 20 | 0.050 |
Why?
| | Placenta | 1 | 2008 | 750 | 0.050 |
Why?
| | Ventricular Remodeling | 1 | 2023 | 266 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2024 | 382 | 0.040 |
Why?
| | Angina, Unstable | 1 | 2000 | 76 | 0.040 |
Why?
| | Enoxaparin | 1 | 2000 | 63 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 548 | 0.040 |
Why?
| | Heparin | 1 | 2000 | 261 | 0.040 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1023 | 0.040 |
Why?
| | Interview, Psychological | 1 | 2019 | 96 | 0.040 |
Why?
| | Telomere | 1 | 2022 | 280 | 0.040 |
Why?
| | Calcitriol | 2 | 1995 | 58 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2071 | 0.040 |
Why?
| | Cholecalciferol | 2 | 1995 | 60 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2000 | 270 | 0.030 |
Why?
| | Diseases in Twins | 1 | 2019 | 169 | 0.030 |
Why?
| | Middle Aged | 5 | 2024 | 33479 | 0.030 |
Why?
| | Hippocampus | 1 | 2022 | 895 | 0.030 |
Why?
| | Thrombocythemia, Essential | 1 | 1996 | 7 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1118 | 0.030 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 1996 | 24 | 0.030 |
Why?
| | Telemedicine | 1 | 2025 | 862 | 0.030 |
Why?
| | Steroid Hydroxylases | 1 | 1995 | 22 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 4030 | 0.030 |
Why?
| | Habituation, Psychophysiologic | 1 | 2015 | 55 | 0.030 |
Why?
| | Vitamin D Deficiency | 2 | 1995 | 186 | 0.030 |
Why?
| | Interferon-alpha | 1 | 1996 | 198 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5472 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2015 | 409 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 1995 | 155 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3457 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 1995 | 283 | 0.030 |
Why?
| | Intestine, Small | 1 | 1995 | 156 | 0.030 |
Why?
| | Species Specificity | 1 | 2015 | 585 | 0.030 |
Why?
| | Secondary Prevention | 2 | 2008 | 233 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 3 | 2013 | 2486 | 0.030 |
Why?
| | Judgment | 1 | 2013 | 60 | 0.030 |
Why?
| | Hypocalcemia | 1 | 1993 | 27 | 0.030 |
Why?
| | Receptors, Dopamine | 1 | 2013 | 20 | 0.030 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2013 | 72 | 0.030 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2013 | 20 | 0.030 |
Why?
| | Myocardial Infarction | 1 | 2000 | 1046 | 0.030 |
Why?
| | Video Recording | 1 | 2013 | 180 | 0.020 |
Why?
| | Primary Health Care | 1 | 2023 | 1738 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2013 | 183 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 2019 | 828 | 0.020 |
Why?
| | Calcium | 2 | 1995 | 1199 | 0.020 |
Why?
| | Communication Barriers | 1 | 2013 | 104 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2892 | 0.020 |
Why?
| | Aged | 3 | 2024 | 23961 | 0.020 |
Why?
| | RNA, Messenger | 3 | 2013 | 2833 | 0.020 |
Why?
| | Brain Mapping | 1 | 2013 | 503 | 0.020 |
Why?
| | Child | 2 | 2022 | 21935 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2035 | 0.020 |
Why?
| | Rats | 3 | 2013 | 5647 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1060 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2992 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 2013 | 433 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2013 | 351 | 0.020 |
Why?
| | ErbB Receptors | 1 | 1993 | 614 | 0.020 |
Why?
| | Fetal Death | 1 | 2008 | 55 | 0.020 |
Why?
| | Executive Function | 1 | 2013 | 451 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 10811 | 0.020 |
Why?
| | Patient Care Team | 1 | 2013 | 631 | 0.020 |
Why?
| | Infant, Low Birth Weight | 1 | 2008 | 141 | 0.020 |
Why?
| | Pre-Eclampsia | 1 | 2008 | 190 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 3556 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 3295 | 0.010 |
Why?
| | Cognition | 1 | 2013 | 1153 | 0.010 |
Why?
| | Animals | 4 | 2015 | 36940 | 0.010 |
Why?
| | Mass Screening | 1 | 2013 | 1287 | 0.010 |
Why?
| | Liver | 1 | 1993 | 1943 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10388 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2607 | 0.010 |
Why?
| | Pilot Projects | 1 | 2008 | 1710 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7635 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 2000 | 73 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2000 | 157 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2000 | 206 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 21513 | 0.010 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 1995 | 15 | 0.010 |
Why?
| | DNA Probes | 1 | 1995 | 60 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2000 | 1993 | 0.010 |
Why?
| | Enzyme Induction | 1 | 1995 | 90 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1995 | 201 | 0.010 |
Why?
| | Incidence | 1 | 2000 | 2804 | 0.010 |
Why?
| | Transforming Growth Factor alpha | 1 | 1993 | 57 | 0.010 |
Why?
| | Aspirin | 1 | 1996 | 387 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 1993 | 177 | 0.010 |
Why?
| | Down-Regulation | 1 | 1995 | 657 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1995 | 1316 | 0.010 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 1996 | 463 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2000 | 5131 | 0.010 |
Why?
| | Phosphorylation | 1 | 1993 | 1759 | 0.000 |
Why?
|
|
Demers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|